PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
about
Anti-angiogenic agents in metastatic colorectal cancerAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer.Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.VEGF/VEGFR signalling as a target for inhibiting angiogenesis.Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.Effect of PTK/ZK on the angiogenic switch in head and neck tumors.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Angiogenesis in head and neck cancer: a review of the literature.Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines.Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma.Newly developed anti-angiogenic therapy in non-small cell lung cancer.
P2860
Q26801911-B6B5967C-8DFA-4BBB-B4A9-8192CB0E6913Q26826817-A2DE5543-BCA9-4A8A-8B37-C4066DA62321Q30358961-E549DD7B-EA7D-4F2F-AE34-BE872453C301Q31063358-7FB3369C-AFDE-480C-A341-2A465D5739D7Q33730122-480E2586-3D81-4658-81FF-23A14A843F76Q36677407-DB21B65B-DFC9-47B2-B5B4-EB4779B316F2Q36736364-E352DA83-A1C7-4D20-8CEC-D4D327900195Q37124065-E6C976BD-DB7B-4B1C-823F-52331B6C8D65Q37124702-34305E30-D297-48DC-91F0-5822F27286C5Q37846342-7AFAC4CA-85EF-4FA8-B6BC-5FBCA9D54242Q37963379-2F84F4C2-586B-45B0-8170-58283323593FQ39384319-DDBC27A7-9489-408E-9899-3989C3D49C72Q39560865-BFD8BA08-7F4C-4863-9FFC-9A3EA3D0EAF3Q39965992-2B1D60AC-3E11-421F-A4BC-749B6794C32DQ41558273-F6F0FB53-C997-4111-A3EF-23D2019DDF7BQ52668159-0B34023B-75AA-44E7-A812-15A2A2A29112
P2860
PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@en
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@nl
type
label
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@en
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@nl
prefLabel
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@en
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@nl
P2093
P2860
P356
P1433
P1476
PTK 787/ZK 222584, a tyrosine ...... mor growth with high efficacy.
@en
P2093
Holger Hess-Stumpp
Karl-Heinz Thierauch
Martin Haberey
P2860
P304
P356
10.1002/CBIC.200400305
P577
2005-03-01T00:00:00Z